Acetylcholinesterase inhibitors and memantine deprescribing guideline

Using the evidence-based deprescribing guideline method established through the Bruyère Research Institute and the Ontario Pharmacy Evidence Network, Dr. Reeve developed an Australian/Canadian focused prescribing guideline for acetylcholinesterase inhibitors and memantine. Next steps include an evaluation of the guideline impact in the Australian context.

Lead: Dr. Emily Reeve

Co-investigators: Dr. Barbara Farrell,

Contact: [email protected]

Funder (2016-2020): National Health and Medical Research Council – Australian Research Council Dementia Research Fellowship


Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin P, Chenoweth L, Gorman M, Quirke L, Bethune G, Forbes F, Hilmer S. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Sydney: University of Sydney. 2018. Available at: